Network Lead Academic Participating Site Grant from the Roswell Park Cancer Institute

罗斯威尔帕克癌症研究所网络领导学术参与站点资助

• 批准号: 10734330
• 负责人: SHASHIKANT LELE
• 金额: $ 2.5万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-06 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10734330
• 关键词: Benign; Cancer Biology; Cancer Patient; Clinical Data; Clinical Research; Clinical Trials; Enrollment; Grant; Institution; Lead; Malignant - descriptor; Molecular; Operative Surgical Procedures; Patient advocacy; Patients; Populations at Risk; Process; Quality of life; Radiation; Radiology Specialty; Research; Research Personnel; Resources; Roswell Park Cancer Institute; Site; Specimen; Techniques; Therapeutic; cancer prevention; cancer therapy; data submission; experience; improved; inter-institutional; novel therapeutics; premalignant; prognostic

PROJECT SUMMARY The Roswell Park Cancer Institute has had a long tradition of contributing to the national cooperative groups over many decades. Those contributions have been scientific, administrative, and participatory (enrollment on clinical trials). Contributions have been consistent and numerous over the years. This application summarizes the intent of its 4 Co-PIs (Levine/Ernstoff/Lele/Singh) and the membership of RPCI to sustain its commitment to the many strengths inherent to cooperative group research: therapeutic advances; a better understanding of the biology of cancer; cancer prevention; means to improve the quality of life of cancer patients; piloting of new drugs and radiologic and radiation and surgical techniques; establishing the relevance of new cellular and molecular advances to the predictive, prognostic, and therapeutic approaches to patients; and the advancement of patient advocacy. Investigators at RPCI and its supporting staff fully recognize the essential importance of the timely and accurate submission of data and specimens to achieve these aims.

项目概要 罗斯威尔帕克癌症研究所有着为国家合作团体做出贡献的悠久传统 几十年来。这些贡献是科学的、行政的和参与性的（注册 临床试验）。多年来，贡献始终如一且数量众多。本应用总结了 4 位联合 PI（Levine/Ernstoff/Lele/Singh）和 RPCI 成员维持其承诺的意图 合作小组研究固有的许多优势：治疗进展；更好地理解 癌症生物学；癌症预防；改善癌症患者生活质量的手段；试点新 药物、放射学、辐射和手术技术；建立新细胞的相关性和 患者预测、预后和治疗方法的分子进展；和 推进患者权益倡导。 RPCI 的研究人员及其支持人员充分认识到这一点 及时、准确地提交数据和样本对于实现这些目标非常重要。